Status:
COMPLETED
Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy
Lead Sponsor:
Fu Jen Catholic University Hospital
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
Background：Helicobacter pylori infection is a well-established risk factor for peptic ulcer disease and gastric cancer. It's now a consensus of experts that H.pylori infection should be treated once i...
Detailed Description
Background：Helicobacter pylori infection is a well-established risk factor for peptic ulcer disease and gastric cancer. It's now a consensus of experts that H.pylori infection should be treated once i...
Eligibility Criteria
Inclusion
- Patients with naive H. pylori infection
- Subjects with over 20 years old
Exclusion
- Younger than 20 years old
- Ever received H. eradication therapy
- ever received total or subtotal gastrectomy in the past
- Severe chronic disease, such as end stage renal disease, liver cirrhosis, incurable malignant tumors
- Women who are pregnant or breastfeeding
- Those who are not suitable to receive study drugs: such as a history of allergies to study drugs or serious side effects, etc.
- Patient with estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 mt2
Key Trial Info
Start Date :
November 14 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 3 2024
Estimated Enrollment :
337 Patients enrolled
Trial Details
Trial ID
NCT06156085
Start Date
November 14 2023
End Date
December 3 2024
Last Update
September 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fu Jen Catholic University Hospital, Fu Jen Catholic University
New Taipei City, Taiwan, 24352